Dianthus Therapeutics has cleared its earnings event with momentum intact — and the data since the print shows shorts retreating while institutional conviction holds firm.
The most notable post-earnings shift is in short positioning. Short interest has edged down to 20.9% of the free float, trimming roughly 1.3% over the week after the sharp build that preceded the report. The month-on-month picture still shows a 22.5% rise in shares short, meaning the base remains large — FINRA's latest official count puts days to cover near 8.9 — but the direction has turned. Borrow conditions do not reinforce the bear case. Cost to borrow remains low at 0.56%, and availability has swung dramatically looser, jumping to 562% — nearly five-and-a-half shares available for every one currently borrowed. That compares to a 52-week low availability of 122%, meaning today's lending market is the most relaxed it has been all year. Shorts sitting on an uncomfortable position face no structural squeeze pressure from the borrow side.
Options positioning confirms the bullish lean. The put/call ratio has dropped to 0.24 — almost four standard deviations below its 20-day average of 0.29. Call demand is running at its most aggressive relative to puts in months, close to the 52-week low PCR of 0.10. That reading preceded the print and has barely moved since, indicating options traders are not unwinding their upside bets. The ORTEX short score has eased from 70 in late July to 64.6 now, consistent with a modest reduction in bearish pressure rather than a full capitulation.
The Street is adding to the constructive case. Wedbush raised its target to $122 on the day of the earnings report itself, while Evercore ISI lifted to $134 two days earlier — both maintaining Outperform ratings. With 14 buy-side ratings and a consensus mean target of $128.58, there is roughly 16% implied upside from the current $110.40 close. The bull case centres on Claseprubart as a potentially best-in-class complement inhibitor, a pipeline spanning three indications for DNTH212, and a cash runway extended to 2030. Bears point to the entirely unproven pipeline and the lack of hard efficacy data underpinning the valuation. Neither the earnings release nor subsequent analyst moves have materially shifted that debate — the Street simply got slightly more optimistic on the numbers.
Institutional ownership reinforces the buy-side tilt. FMR added 1.3 million shares to reach 14.2% of the company, T. Rowe Price added 1.8 million shares to reach 4.5%, and BlackRock added 417,000 to hit 6.4% — all as of the most recent June quarter-end filing. That represents meaningful active accumulation at prices below where the stock trades today. The insider picture is less clean: CFO Ryan Savitz sold just over $3.1 million across three tranches on July 9th at around $100-102, and the General Counsel sold approximately $2.4 million in June. Net insider activity is slightly positive over 90 days only in the sense that options exercises and grants offset open-market sales — but the directional read from C-suite open-market activity is cautious.
The divergence between a bullish options market, easing short interest, and active institutional buying on one side, and persistent CFO selling and a still-heavy 21% short base on the other, is the tension worth watching into the next catalyst — the November earnings date — alongside any interim clinical data announcements on Claseprubart or DNTH212 that could resolve the core bull-bear debate on pipeline validity.
See the live data behind this article on ORTEX.
Open DNTH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
